No title
This study examines whether cross-border out-licensing announcements by Chinese listed biopharmaceutical firms generate positive abnormal returns and which mechanisms explain these reactions. Using 229 out-licensing events involving 62 Chinese listed firms from January 2020 to February 2026, the study conducted event-study and event-level cross-sectional regressions. The results show that announce
